Atlanta Capital Partners, LLC

EVFM Evofem Biosciences on the NASDAQ - 12.5 million shares out, $14 million market cap, over $12 million in trailing 12 sales, and a huge fat short position! FDA-approved Phexxi vaginal gel is a hormone-free, on-demand prescription form of birth control. Big catalyst - Evofem received confirmation three weeks ago from one of the largest Pharmacy Benefit Managers (PBMs) in the nation that they will add Phexxi to their national template formularies with no restrictions. PBMs are companies that manage prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers, and other payers. Three large PBMs — CVS, Express Scripts, and UnitedHealth's Optum — account for more than 70 percent of claims volume.

Evofem InvestorRoom - Company Overview Investor Overview Stock InformationLoading data... Press Releases May 10, 2022 Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi® Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it ha...

Atlanta Capital Partners, LLC's proactive campaigns are custom designed to strengthen each client's presence in the investment community by disseminating breaking news and fundamental positions to key decision makers, servicing existing shareholders, and soliciting institutional coverage. Let us know how we can help you achieve better results. http://www.atlcp.com/ir%20services/default.html